0.000USD0.000盘前交易 08/03, 09:30 (美东)
关键数据
5.550今开
5.605最高
2.08M成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
2.10%换手率
5.630昨收
5.110最低
7.28M成交额
63.69市盈率静
4.46市净率
0.00%股息率 TTM
-64.39%ROA
18.90052周最高
0.78量比
8.00M净利润
99.29M总股本
-2.0023每股收益TTM
0.94Beta
-136.40%ROE
6.66052周最低
8.79%振幅
72.29%毛利率
509.43M总市值
-8.01回报/风险
4.05%风险率
操作建议
ARS Pharmaceuticals Inc当前公司基本面数据相对稳定,增长潜力较大。当前估值合理,在生物技术与医疗研究行业排名24/385位。机构持股占比非常高,近一月多位分析师给出公司评级为强力买入。最高目标价29.75。中期看,股价处于下降通道。近一个月,市场表现非常差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
ARS Pharmaceuticals Inc评分
压力支撑

由于公司未披露,未能获取相关数据
ARS Pharmaceuticals Inc亮点
亮点风险
ARS Pharmaceuticals Inc新闻
即将为您带来更多新闻,敬请期待。。。
收益预测
ARS Pharmaceuticals Inc
SPRY
4
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
ARS Pharmaceuticals Inc简介
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
公司代码SPRY
公司ARS Pharmaceuticals Inc
CEOLowenthal (Richard E)
网址https://ars-pharma.com/
公司股东
常见问题
ARS Pharmaceuticals Inc(SPRY)的当前股价是多少?
ARS Pharmaceuticals Inc(SPRY)的当前股价是 5.13。
ARS Pharmaceuticals Inc的股票代码是什么?
ARS Pharmaceuticals Inc的股票代码是SPRY。
ARS Pharmaceuticals Inc股票的52周最高点是多少?
ARS Pharmaceuticals Inc股票的52周最高点是18.90。
ARS Pharmaceuticals Inc股票的52周最低点是多少?
ARS Pharmaceuticals Inc股票的52周最低点是6.66。
ARS Pharmaceuticals Inc的市值是多少?
ARS Pharmaceuticals Inc的市值是509.43M。
现在ARS Pharmaceuticals Inc(SPRY)的股票是买入、持有还是卖出?
根据分析师评级,ARS Pharmaceuticals Inc(SPRY)的总体评级为STRONG BUY,目标价格为29.75。
ARS Pharmaceuticals Inc(SPRY)股票的每股收益(EPS TTM)是多少
ARS Pharmaceuticals Inc(SPRY)股票的每股收益(EPS TTM)是-1.74。